We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Accustem Sciences Inc (ACUT) USD0.001

Sell:$0.24 Buy:$0.24 Change: No change
Market closed |  Prices as at close on 17 December 2024 | Switch to live prices |
Sell:$0.24
Buy:$0.24
Change: No change
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 December 2024 | Switch to live prices |
Sell:$0.24
Buy:$0.24
Change: No change
Market closed |  Prices as at close on 17 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AccuStem Sciences, Inc. is a clinical-stage diagnostics company. The Company is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. The Company's product candidate is StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. In addition, the Company is focused on offering ancillary commodity testing (hereditary genetic testing, somatic mutation testing) that augments its assays and provides additional information to patients and physicians throughout the patient care continuum. The Company also holds licensing rights for the MicroRNA Signature Classifier (MSC) test, which is designed to help determine whether lung nodules identified by low-dose computed tomography (LDCT) screening are benign or malignant. The Company's wholly owned subsidiary is StemPrintER Sciences Limited.

Contact details

Address:
5 Penn Plaza, 19th Floor, #1954
NEW YORK
10001
United States
Telephone:
+1 (207) 0661000
Website:
https://accustem.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ACUT
ISIN:
US00444A1016
Market cap:
$2.75 million
Shares in issue:
11.35 million
Sector:
Biotechnology
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Wendy Blosser
    Chief Executive Officer, Director
  • Keeren Shah
    Chief Financial Officer
  • Jeff Fensterer
    Chief Operating Officer
  • Joe Flanagan
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.